Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington. Show more
Location: 22722 29th Dr. SE, Bothell, WA, 98021, United States | Website: https://www.achievelifesciences.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
115.3M
52 Wk Range
$1.84 - $5.31
Previous Close
$2.33
Open
$2.33
Volume
355,579
Day Range
$2.25 - $2.34
Enterprise Value
65.1M
Cash
23.25M
Avg Qtr Burn
-8.893M
Insider Ownership
9.69%
Institutional Own.
41.59%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Cytisinicline Details Smoking cessation | NDA Acceptance for review | |
Cytisinicline Details Smoking cessation | Phase 3 Initiation |